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Background: The clinical and demographic variables defining the heterogeneity of chronic
obstructive pulmonary disease (COPD) are unclear. A post-hoc analysis of five randomised
studies in patients with a history of previous exacerbations examined the clinical and demo-
graphic characteristics describing moderate-to-very-severe COPD.
Methods: Factor analysis was performed on all continuous baseline demographic and clinical
data, without variable selection. Analyses were based on the full cohort and on stratifications
by pack-years smoked, smoking status, gender, and comorbidities; patient exacerbation his-
tory was analysed in two of the five studies.
Findings: 6162 COPD patients were evaluated (70% male; 40% current smokers; mean pre-)503613532; fax: þ31 (0)503619320.
.nl (D.S. Postma).
3 Published by Elsevier Ltd.
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1940 D.S. Postma et al.bronchodilator forced expiratory volume in 1 s [FEV1] 35.2% predicted). Baseline clinical and
demographic variables loaded differentially on six factors with minimal overlap, explaining
60.4% of the heterogeneity: 1) symptoms (cough, dyspnoea, sleep disturbance), health status,
reliever use; 2) pre-bronchodilator FEV1, FEV1/forced vital capacity, morning peak expiratory
flow (PEF), body mass index (BMI); 3) blood pressure; 4) age, months since first COPD symp-
toms; 5) PEF variability; 6) pulse, FEV1 reversibility. Most factors loaded similarly in stratified
and exacerbation analyses. BMI loaded with reversibility in females, and with age and months
since first COPD symptoms in ex-smokers. Exacerbations loaded to factor 6.
Interpretation: Readily available data can explainw60% of COPD heterogeneity in a large da-
taset of predominantly severe COPD patients. Factors were robust over determinants of dis-
ease outcome; gender, smoking status, pack-years smoked, and comorbidities. The main
factors were largely unchanged by adding exacerbations. Only BMI loaded to other factors.
ª 2013 Published by Elsevier Ltd.Background
Chronic obstructive pulmonary disease (COPD) is associated
with smoking and biomass smoke exposure, and has a major
impact on global healthcare costs [1]. COPD was one of the
leading causes of disability in 2010 [2] and is predicted to
be the third leading cause of mortality by 2030 [3]. Effec-
tive treatment is complicated by the clinical, physiological,
and pathological heterogeneity of this condition [4]. Clin-
ical presentation varies, and symptoms (cough, phlegm,
and dyspnoea) may occur alone or in combination at every
stage. COPD is associated with progressive persistent
airflow limitation and accelerated lung function decline [5].
There is considerable variability in lung function decline [6]
and heterogeneity in the pathological processes underlying
COPD [7].
Accurate assessment of COPD severity is important in
guiding management. The Global initiative for chronic
Obstructive Lung Disease (GOLD) divides COPD severity into
four grades, based on airflow limitation, symptoms, and
exacerbation history [5]. COPD management should not be
based solely on lung function, since clinical characteristics
(e.g. exacerbations and health-related quality of life
[HRQL]) can be improved, irrespective of GOLD grade [8,9].
It is unknown how COPD subtypes, defined by clinical and
demographic characteristics, are influenced by in-
terventions or how they relate to other clinical character-
istics. Identification of COPD phenotypes will allow more
focused research on disease biomarkers, and thus more
specific treatment strategies [10]. One of the challenges is
to develop such phenotypes in an objective way indepen-
dently of investigator bias.
We examined whether clinical and demographic char-
acteristics of specific COPD patient subsets can be obtained
from a dataset of patients in clinical trials. Factor analysis
was performed using baseline characteristics from five
studies [11e15]. We assessed how patient characteristics
potentially influencing disease severity, outcome, and
management could be clustered. Analyses were stratified
for smoking status, gender, pack-years smoked, and
comorbidities. Moreover, since exacerbations predict
future outcomes [8], we analysed the two studies with in-
formation on past number of exacerbation separately
[12,14]. We anticipated that differences would emerge
within these groups based on this approach, which isindependent of pre-existing biases, providing insight into
variables that characterise a large group of COPD patients.Methods
Baseline data were analysed from five trials involving COPD
patients with a history of exacerbation in the past year,
pre-bronchodilator FEV1 50% predicted and FEV1/vital
capacity (VC) [11,13] or FEV1/forced VC (FVC) [12,14,15]
<70%, and smoking history 10 pack-years [11e15]. All
continuous baseline demographic and clinical data were
used, without selection of variables, to ensure an unbiased
approach. FEV1 reversibility was assessed with salbutamol
(albuterol; 180e200 mg) [12,14] or terbutaline (two in-
halations, 0.5 mg/inhalation) [11,13,15] and expressed as
increase in FEV1 % predicted. Height, weight, systolic/dia-
stolic BP, and pulse were assessed at run-in and St George’s
Respiratory Questionnaire (SGRQ) [16] scores at run-in
completion. Peak expiratory flow (PEF) absolute values,
PEF variability ([morning PEFeevening PEF]/morning PEF),
symptom scores (cough, breathlessness, nocturnal awak-
ening due to dyspnoea), and reliever use were calculated
from patient diaries. Symptoms were scored using a 5-point
Likert scale. Comorbidities were derived from patient re-
ports of physician-diagnosed ischaemic cardiovascular dis-
ease, arteriosclerosis, hypertension, depression, anxiety,
gastroesophageal reflux, and diabetes; these were com-
bined to reduce the parameters. Time (months) since COPD
symptom onset was determined from case report forms.
Factor analysis was performed to determine which
characteristics were closely related. The covariance
structure of baseline variables is described using classical
principal component analysis (PCA), which does not require
specific distributional properties of data, followed by an
orthogonal rotation using the varimax principle [17]. The
importance of factors is described by scree plots, and the
number of components retained in the rotated structure
determined by the eigenvalue one criterion and the pro-
portion of total heterogeneity explained by these factors.
For stratified analyses, supplementary rotations provided
factor structures with the same number of factors for both
sub-groups, allowing direct comparisons. Analyses were
stratified by gender, pack-years smoked (<40 or 40 pack-
years), smoking status (current or ex-smokers), and
Table 1 Baseline characteristics of patients with COPD participating in the five studies included in the analysis.
Characteristic Rennard
et al. [12]
NCT00206167
(n Z 1964)
Tashkin
et al. [14]
NCT00206154
(n Z 1704)
Welte
et al. [15]
NCT00496470
(n Z 660)
Calverley
et al. [11] a
(n Z 1022)
Szafranski
et al. [13] a
(n Z 812)
All
(n Z 6162)
Age, years 63.1 (9.1) 63.4 (9.1) 62.4 (8.7) 64.0 (9.0) 64.2 (8.9) 63.4 (9.1)
Male, n (%) 1255 (63.9) 1161 (68.1) 496 (75.2) 770 (75.3) 641 (78.9) 4323 (70.2)
BMI, kg/m2 27.0 (5.8) 26.6 (5.6) 26.4 (5.2) 24.3 (4.8) 25.1 (5.1) 26.1 (5.5)
Pulse, bpm 77.2 (10.6) 77.7 (10.6) 78.1 (10.6) 79.5 (9.4) 78.4 (11.9) 78.0 (10.6)
DBP, mmHg 78.5 (9.6) 79.0 (9.7) 79.6 (9.5) 81.0 (10.2) 81.3 (10.2) 79.5 (9.7)
SBP, mmHg 131.3 (15.9) 131.6 (15.7) 132.9 (16.5) 134.8 (16.0) 134.1 (17.6) 132.5 (16.2)
Smoking history:
Ex-smokers, n (%) 1130 (57.5) 980 (57.5) 370 (56.1) 669 (65.5) 532 (65.5) 3681 (59.7)
Current smokers, n (%) 834 (42.5) 1049 (61.6) 568 (86.1) 700 (68.5) 393 (38.5) 3922 (63.6)
Smoking history, pack-years 46.9 (27.2) 46.0 (26.3) 40.7 (22.8) 38.7 (22.5) 44.4 (24.8) 44.3 (25.6)
Months since first
COPD symptoms
129.7 (86.2) 126.0 (86.3) 88.9 (76.1) 150.0 (111.4) 128.7 (90.9) 127.6 (91.8)
Pre-bronchodilator
FEV1, % predicted
34.4 (9.4) 34.2 (9.5) 37.9 (8.6) 36.1 (9.7) 36.1 (9.7) 35.2 (9.5)
Pre-bronchodilator
FEV1, % VC or FVC
48.3 (10.2) 47.0 (10.3) 47.1 (10.6) 43.5 (11.7) 42.5 (12.0) 46.2 (11.0)
Post-bronchodilator
FEV1, % predicted
39.6 (11.5) 39.8 (11.9) 43.5 (11.3) 42.1 (12.3) 41.8 (11.5) 40.8 (11.8)
GOLD Grade 4, n (%) 423 (21.5) 375 (22.0) 75 (11.4) 173 (16.9) 128 (15.8) 1174 (19.1)
GOLD Grade 3, n (%) 1187 (60.4) 991 (58.2) 420 (63.6) 569 (55.7) 488 (60.1) 3655 (59.3)
GOLD Grade 2, n (%) 349 (17.7) 329 (19.3) 160 (24.2) 275 (26.9) 186 (22.9) 1299 (21.1)
GOLD Grade 1, n (%) 2 (0.1) 5 (0.3) 4 (0.6) 2 (0.2) 3 (0.4) 16 (0.3)
FEV1 reversibility, % predicted 5.3 (5.6) 5.6 (6.0) 5.6 (7.3) 5.8 (6.3) 5.8 (6.4) 5.6 (6.1)
Morning PEF, % predicted 41.7 (13.8) 41.1 (12.9) 35.2 (12.5) 46.1 (14.7) 40.5 (12.4) 41.4 (13.7)
PEF variability 0.1 (0.1) 0.1 (0.1) 0.2 (0.2) 0.1 (0.1) 0.1 (0.1) 0.1 (0.1)
SGRQ scores:
Total score 55.0 (16.7) 55.5 (16.4) 62.2 (17.6) 48.2 (18.4) 52.4 (16.5) 54.5 (17.4)
Symptom score 66.4 (19.0) 65.3 (19.6) 73.2 (17.5) 57.3 (20.3) 62.0 (18.9) 64.7 (19.7)
Impact score 43.0 (19.5) 44.3 (19.7) 51.8 (21.9) 41.3 (21.9) 43.8 (19.7) 44.1 (20.4)
Activity score 69.9 (18.5) 69.7 (17.4) 73.5 (19.0) 60.0 (21.0) 66.8 (19.3) 68.2 (19.2)
Reliever use:
During the night 0.7 (1.1) 0.6 (1.1) 1.1 (1.1) 0.4 (0.8) 0.6 (0.9) 0.6 (1.0)
During the day 3.2 (2.8) 2.9 (3.0) 3.1 (2.4) 1.4 (1.8) 3.2 (2.8) 2.8 (2.8)
Comorbidities, n (%) 1256 (64.0) 1054 (61.9) 379 (57.4) 365 (35.7) 280 (34.5) 3334 (54.1)
All values expressed as mean (standard deviation), unless otherwise stated. PEF variability is defined as (morning PEF e evening PEF)/
morning PEF. GOLD grades include FEV1%predicted as follows: GOLD Grade 1  80% predicted, GOLD Grade 2 50e80% predicted, GOLD
Grade 3 30e50%predicted, GOLD Grade 4  30% predicted.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; FEV1, forced expiratory volume in
1 s; FVC, forced vital capacity; GOLD, Global initiative for chronic Obstructive Lung Disease; PEF, peak expiratory flow; SBP, systolic
blood pressure; SGRQ, St George’s Respiratory Questionnaire; VC, vital capacity.
a These studies have no registration numbers, as they were conducted before clinical trial registration was required.
Identifying COPD heterogeneity using factor analysis 1941comorbidities (with or without). We also examined the
impact of exacerbations, based on the two of the five
studies with data on patient exacerbation history [12,14].
Results tables are presented with rotated factor loadings,
with variables sorted by factor with largest absolute
loading.
Pre- and post-bronchodilator FEV1 and FEV1 reversibility
were co-linear, therefore post-bronchodilator FEV1 was not
analysed. Since morning and evening PEF and PEF variability
were almost co-linear, evening PEF was omitted. Thus 16
characteristics were examined: age, body mass index (BMI),
pre-bronchodilator FEV1, pre-bronchodilator FEV1/FVC
[11,12,14] or FEV1/VC [13,15], FEV1 reversibility, SGRQ totalscore, months since first COPD symptoms, systolic and dia-
stolic BP, pulse, morning PEF, PEF variability, scores of
breathlessness, cough, sleep disturbance, and reliever use.
Patients with missing values were removed from anal-
ysis; potential bias was investigated with comparative
summaries of included and excluded patients.Results
Baseline clinical and demographic characteristics of patients
were comparable. All patients (n Z 6162; 70% male) had
moderate-to-very-severe COPD (defined by post-
1942 D.S. Postma et al.bronchodilator FEV1 [GOLD criteria] [5] (Table 1). Included
and excluded patients had similar characteristics
(Supplementary Table 1).
The 16 demographic and clinical characteristics loaded
over six factors with minimal overlap, explaining 60.4% of
the total COPD heterogeneity, are described in Table 2.
The importance of factors was determined by scree
plots, with the number of components retained in the
rotated structure determined by eigenvalue one criterion,
variables being sorted according to largest absolute
loading. PEF variability is described as factor 5, and FEV1
reversibility and pulse are described as factor 6 in the sub-
analyses.Figure 1 Scree plot of the full data set. PCA, principal
component analysis.Stratified analysis
Factor analyses of the total and stratified groups are shown
in Fig. 1, Table 4 and Supplementary Tables 2e5, respec-
tively. Variables loading on different factors in the total
and stratified analyses are highlighted.Gender
Females were slightly younger than males (mean 62 vs. 64
years), had smoked less (39 vs. 47 pack-years), were more
often current smokers (47% vs. 37%), and had slightly better
lung function (post-bronchodilator FEV1 43% vs. 40% pre-
dicted; Supplementary Table 6). SGRQ activity scores were
higher (72 vs. 67) and comorbidities were more common
(58% vs. 53%) in females than males. BMI and PEF variability
were comparable between genders.
In females, BMI did not load with lung function (factor 2,
0.21) as in males (0.43) and the total group (0.40;
Supplementary Table 2), instead loading with FEV1 revers-
ibility. Pulse changed its loading from FEV1 reversibility (as
in the total group) to BP (factor 3, 0.35). Gender differ-
ences in SGRQ activity scores necessitated the SGRQ totalTable 2 Demographic and clinical characteristics loaded
over six factors explaining 60.4% of the total COPD
heterogeneity.
Factor
1 16.2% Breathlessness, cough and sleep
disturbance due
to respiratory symptoms, SGRQ total
score, and reliever use
2 12.0% Pre-bronchodilator FEV1, pre-bronchodilator
FEV1/(F)VC, morning PEF, and BMI
3 10.3% SBP and DBP
4 7.6% Age and months since first COPD symptoms
5 7.1% PEF variability
6 7.1% FEV1 reversibility and pulse
BMI, body mass index; COPD, chronic obstructive pulmonary
disease; DBP, diastolic blood pressure; FEV1, forced expiratory
volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory
flow; SBP, systolic blood pressure; SGRQ, St George’s Respira-
tory Questionnaire.score being replaced by the sub-domains; this did not
change the results (data not shown).
Pack-years smoked
There were minimal differences in the demographic and
clinical characteristics of patients with a smoking history
<40 and 40 pack-years (Supplementary Table 7). Patient
characteristics were distributed across the six factors in a
similar manner for the pack-year sub-divisions
(Supplementary Table 3) as the total group (Table 3).
In patients with a smoking history <40 pack-years, BMI
loaded with lung function (factor 2, 0.48), consistent with
the total group (0.40). However, BMI loaded almost equally
to lung function and FEV1 reversibility and pulse (0.36 and
0.38, respectively) in the group with 40 pack-years. Pulse
loaded equally (0.35) on FEV1 reversibility and on age and
months since first COPD symptoms (factor 4) in the group
with <40 pack-years, in contrast to the total group, where
pulse loaded with factor 6.
Smoking status
Current and ex-smokers had comparable demographic and
clinical characteristics (Supplementary Table 8). Current
smokers were slightly younger than ex-smokers (mean 60
vs. 66 years), with worse cough (1.9 vs. 1.4) and SGRQ
symptom scores (69.3 vs. 61.6). However, tobacco exposure
was similar between the groups (45 vs. 44 pack-years).
In current smokers, BMI loaded with lung function (fac-
tor 2, 0.51) but not FEV1 reversibility and pulse (0.18),
consistent with BMI loadings in the total group (0.40 and
0.24, factor 2 and 6, respectively). In contrast, BMI did not
load with lung function in ex-smokers (0.29), instead
loading with factor 4 (0.48). Otherwise, loadings were
comparable in terms of combinations and values, and when
SGRQ sub-domains versus SGRQ total scores were analysed.
Comorbidities
Patients with and without self-reported comorbidities had
comparable demographic and clinical characteristics
Table 3 Factor loadings in the total group of patients with COPD in the five studies (n Z 6162).
Variable 1 2 3 4 5 6
Breath symptom score 0.79 0.10 0.00 0.05 0.00 0.02
Cough symptom score 0.73 0.13 0.04 0.12 0.02 0.04
SGRQ total score 0.73 0.05 0.01 0.02 0.11 0.11
Sleep symptom score 0.70 0.07 0.00 0.02 0.09 0.04
Reliever use 0.52 0.26 0.02 0.05 0.24 0.05
Pre-bronchodilator FEV1, % predicted 0.14 0.81 0.02 0.01 0.03 0.03
Pre-bronchodilator FEV1, % VC or FVC 0.06 0.85 0.03 0.03 0.04 0.06
Morning PEF, % predicted 0.23 0.51 0.07 0.03 0.40 0.37
BMI, kg/m2 0.15 0.40 0.26 0.01 0.09 0.24
DBP, mmHg 0.01 0.00 0.88 0.10 0.03 0.04
SBP, mmHg 0.05 0.04 0.86 0.18 0.01 0.03
Age, years 0.18 0.04 0.02 0.75 0.01 0.07
Months since first COPD symptoms 0.11 0.01 0.04 0.69 0.03 0.02
PEF variability, % 0.02 0.05 0.01 0.04 0.94 0.05
Pulse, bpm 0.04 0.08 0.23 0.27 0.07 0.45
FEV1 reversibility, % predicted 0.03 0.01 0.06 0.17 0.08 0.84
Variability explained, %a 16.2 12.0 10.3 7.6 7.1 7.1
PEF variability is defined as (morning PEF e evening PEF)/morning PEF.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; FEV1, forced expiratory volume in
1 s; FVC, forced vital capacity; GOLD, Global initiative for chronic Obstructive Lung Disease; PEF, peak expiratory flow; SBP, systolic
blood pressure; SGRQ, St George’s Respiratory Questionnaire; VC, vital capacity.
Figures in bold and italic indicate the loading of factors.
a Total Z 60.4.
Table 4 Principal component analyses for the total group, and by stratifications, among patients with COPD.
Variable Total Gender Smoking history
(pack-years)
Smoking status Absence/
presence of
comorbidities
Male Female <40 40 Ex Current Absent Present
Breath symptom 0.79 0.80 0.76 0.79 0.79 0.76 0.82 0.80 0.77
Cough symptom 0.73 0.74 0.73 0.74 0.73 0.74 0.75 0.76 0.72
SGRQ total 0.73 0.73 0.73 0.72 0.74 0.73 0.72 0.74 0.72
Sleep symptom 0.70 0.70 0.69 0.74 0.66 0.68 0.70 0.70 0.69
Reliever use 0.52 0.52 0.51 0.53 0.50 0.51 0.51 0.54 0.50
Pre-bronchodilator FEV1, % predicted 0.81 0.80 0.84 0.78 0.83 0.84 0.77 0.83 0.83
Pre-bronchodilator FEV1, % VC or FVC 0.85 0.85 0.82 0.85 0.84 0.83 0.84 0.84 0.85
Morning PEF, % predicted 0.51 0.51 0.49 0.49 0.53 0.55 0.49 0.53 0.49
BMI, kg/m2 0.40 0.43 0.60a 0.48 0.36d 0.48b 0.51 0.33f 0.30
DBP, mmHg 0.88 0.87 0.87 0.87 0.89 0.87 0.89 0.85 0.89
SBP, mmHg 0.86 0.86 0.85 0.85 0.87 0.86 0.89 0.85 0.89
Age, years 0.75 0.77 0.71 0.72 0.76 0.78 0.74 0.70 0.76
Months since first COPD symptoms 0.69 0.67 0.74 0.72 0.68 0.61 0.60 0.66 0.57
PEF variability 0.94 0.93 0.94 0.93 0.94 0.92 0.92 0.94 0.90
Pulse 0.45 0.42 0.35c 0.35e 0.41 0.47 0.67 0.79 0.41
FEV1 reversibility, % predicted 0.84 0.87 0.77 0.89 0.84 0.75 0.68 0.50 0.88
BMI, body mass index; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; FEV1, forced expiratory volume in
1 s; FVC, forced vital capacity; GOLD, Global initiative for chronic Obstructive Lung Disease; PEF, peak expiratory flow; SBP, systolic
blood pressure; SGRQ, St George’s Respiratory Questionnaire; VC, vital capacity.
a Loads with FEV1 reversibility.
b Loads with Age and Months since first COPD symptoms.
c Loads with blood pressure.
d Almost equally loading with reversibility (0.38).
e Equally loading on reversibility (0.35), and on age and months since first COPD symptoms (0.35).
f Loads on lung function (0.33) and on BP (0.40), see Supplementary Tables in the online data repository for further information. PEF
variability is defined as (morning PEF e evening PEF)/(morning PEF).
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1944 D.S. Postma et al.(Supplementary Table 9). Patients without comorbidities
versus with comorbidities were more often male (73% vs.
68%) and current smokers (42% vs. 38%). Patients without
comorbidities also had a slightly lower BMI (24.8 vs.
27.2 kg/m2), FEV1 reversibility (5.4% vs. 5.7%), daily re-
liever use (3.3 vs. 3.6), breathlessness score (1.9 vs. 2.0),
SGRQ total score (52.7 vs. 56.0), and SGRQ activity score
(65.6 vs. 70.3), whereas pulse was comparable (78 vs.
78 bpm) between the groups.
BMI loaded comparatively on lung function (factor 2) and
BP (factor 3) (0.33 and 0.40, respectively) in the group
without comorbidities, and with lung function (factor 2),
and age and months since first COPD symptoms (factor 4) in
the group with comorbidities (0.30 and 0.36, respectively)
(Supplementary Table 5). FEV1 reversibility loaded similarly
with factor 4 (0.44) and factor 5 (0.50 in combination
with pulse) in the group without comorbidities. Results did
not change when analysing SGRQ sub-domains versus the
total score.Exacerbations
Factor analysis on the studies with data on patient exac-
erbation history [12,14] (Supplementary Tables 10 and 11)
showed that factors 1e4 were comparable to the total
group; only reversibility shifted from pulse (factor 6) to PEF
variability (factor 5). When adding prior exacerbations to
the model, exacerbations loaded to factor 6 with pulse.Discussion
We used a series of clinical and demographic characteristics
to investigate the heterogeneity of moderate-to-very-
severe COPD in a large group of COPD patients partici-
pating in five clinical trials [11e15]. Six clusters of char-
acteristics explained w60% of COPD heterogeneity: 1)
respiratory symptoms, reliever use, and HRQL, 2) lung
function and BMI, 3) BP, 4) age and time since first COPD
symptoms, 5) PEF variability, and 6) bronchodilator
responsiveness and pulse.
All continuous baseline variables were assessed, without
selection of variables, thereby ensuring an unbiased
approach. Respiratory symptoms, reliever use, and HRQL
loaded together strongly as one factor over all stratified
analyses. This was also true for lung function variables,
diastolic and systolic BP, age and time since first COPD
symptoms, PEF variability, and FEV1 reversibility. In
contrast, BMI loaded with lung function in the total cohort
and in males, those with <40 pack-years, current smokers,
and those with comorbidities, but with FEV1 reversibility in
females, and with age and months since first COPD symp-
toms in ex-smokers. This is interesting given the indepen-
dent relationship of BMI to accelerated lung function
decline in similar patients [18]. Smoking history had mini-
mal impact, as similar factor loadings existed in the pack-
year stratifications, consistent with previous studies [10].
This does not mean that smoking is unimportant in disease
development but that, once established, the prior smoking
intensity is not a key variable distinguishing between sub-
groups of patients. Smoking status affected factorloadings in ex-smokers, with a shift in BMI from lung func-
tion to age and months since first COPD symptoms.
Females had different factor loadings to males, as pulse
loaded with BP and BMI loaded with FEV1 reversibility. Pa-
tients with and without comorbidities had similar factor
loadings to the total group. Comorbidities in COPD patients
require complex care, with potential diagnostic difficulties
and increased hospitalisation risk. Further analyses are
required to determine the risks associated with specific
comorbidities. We found that most patient characteristics
are robust and independent measures of COPD, while
others (e.g. BMI) are influenced by gender and smoking
cessation.
Prior exacerbations are an important determinant of
future exacerbations, which are also a driver of COPD
prognosis [8]. We therefore separately analysed the two
cohorts with data on patient exacerbation history. Inter-
estingly, this did not increase the explanation of variance in
COPD heterogeneity (60.4% without exacerbations, 57.6%
with exacerbations included), and exacerbations loaded on
factors with the least explanatory value. Alternative clini-
cally relevant factors may explain the remaining COPD
variance, including emphysema type, small airway disease,
and exercise capacity. Nevertheless, the current analysis
has identified important variables explaining COPD het-
erogeneity and these were robust over the five cohorts
studied.
Consistently with previous studies, we have demon-
strated that the clinical manifestations of COPD are vari-
able and that the degree of airflow limitation does not
capture disease heterogeneity [4]. Few studies have used
factor or cluster analyses in assessing the multidimensional
nature of COPD. Celli et al. reported that six factors
explained the heterogeneity of severe COPD (lung function,
symptoms, health status, FEV1 reversibility, BMI plus
walking distance, and dyspnoea plus reliever use) [19]. In
contrast, we have demonstrated that other variables can
influence BMI. The differential findings may be related to
sample size and gender differences between the studies;
the analysed characteristics also differed, as Celli et al. did
not examine PEF variability. Another study investigating
COPD heterogeneity in patients with all COPD stages iden-
tified three factors; 1) SGRQ and modified Medical Research
Council dyspnoea score, 2) age and smoking history, and 3)
BMI and FEV1 [20], consistent with our findings that FEV1
loads with BMI while respiratory symptoms load with HRQL.
We have extended previous findings by showing that FEV1
reversibility and pulse load on one factor, and that PEF
variability is independent. Although BMI was a variable
factor, most other factors were robust throughout the
stratified analyses.
A novel finding was that PEF variability does not cluster
with other variables, appearing as a single factor. Circadian
PEF variation has a weak relationship with hyper-
responsiveness, symptoms, FEV1, and bronchodilator
response in asthma [21e23]. Therefore, these measures
may provide different information regarding disease
severity. Our data indicate that PEF variability is different
from spirometry, FEV1 reversibility, respiratory symptoms,
and reliever use, consistent with reports that COPD symp-
toms worsen during the morning [24]. Further investigations
should assess how increased PEF variability affects the
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impact of treatment [25]. However, like bronchodilator
reversibility, PEF variability explains only a small propor-
tion of COPD heterogeneity.
This study has important strengths. The patient group
was large with variability between patients in all analysed
characteristics. Patient-oriented outcomes were included,
but also BP and pulse, with potential implications for
COPD management and outcomes. All available baseline
variables were analysed, including surrogate measures
of cardiovascular disease (concomitant medications),
therefore the parameters were unbiased. All studies had
similar inclusion/exclusion criteria, using the same data
acquisition and collection methodology. We could there-
fore assess PEF variability as a parameter for COPD
heterogeneity.
A study limitation is that patients in the current analysis
were at the more severe end of the disease spectrum; pa-
tients with mild COPD were excluded and those with
moderate COPD accounted for 21% of the study population.
However, most patients seeking medical advice have more
severe airflow limitation and are symptomatic. Our inclu-
sion of patients with moderate-to-very-severe COPD re-
flects the typical patient population seeking medical
advice, those most commonly seen in clinical practice, and
those with the largest impact on COPD healthcare costs.
COPD subtype classification may be beneficial for such pa-
tients, potentially leading to the development of more
targeted and effective therapies. We have clustered
comorbidities, as these reflect the complexity of disease
care and diagnosis, and hospitalisation risk in COPD; this
risk increases with more comorbidities [26,27]. Although
our estimation of comorbidities was not as rigorous as with
the prospective collection of data in a systematic manner,
concomitant medications are likely to signal clinically
important disease. The lower prevalence of comorbidities
in, predominantly male, smokers may suggest under-
reporting and shows the need for prospective, objective
studies. Physical activity data were not available from the
five clinical trials we analysed. This parameter may influ-
ence the variable clustering variables, but recording such
data requires patient attendance at specialist centres. A
strength of our study is that simple measures available to
many GPs, clinicians, and specialists were used, therefore
the study has relevance to healthcare providers across the
COPD field.
COPD prevalence in females is increasing, therefore
analyses were stratified by gender. Consistent with other
reports, females had worse HRQL despite slightly better
post-bronchodilator FEV1 values. Factor analysis showed
BMI loading with lung function in males (as in the total
group), but loading strongly with reversibility in females.
This difference was not related to BMI differences (males
26.1 kg/m2, females 26.2 kg/m2), potentially reflecting
the higher bronchodilator response in females [28]. Airway
hyperresponsiveness has also been associated with female
obesity [29]; the reason for this remains unclear.
Recent respiratory symptom measures in conjunction
with other objective disease surrogates are needed to
assess the complexity of COPD. Composite measures such as
the body mass index, airflow obstruction, dyspnoea, and
exercise capacity (BODE) index have been developed [30],but this does not fully capture the COPD spectrum. It is
important to assess whether interventions aiming to
improve these factors will change disease outcomes [25].
Our findings were robust in the five cohorts and the sub-
analysis in two cohorts with data on patient exacerbation
history. Nevertheless the results need replication in large
datasets, with patients from GP and specialist care centres,
covering the full spectrum of COPD severity. Clinical and
biological parameters signifying disease progression should
also be examined.
Conclusions
We have identified variables in a large dataset that de-
scribes the heterogeneity of COPD. The six factors were
robust, explaining w60% of COPD heterogeneity in a pop-
ulation with predominantly severe but also some moderate
disease, and include important determinants of disease
outcome, such as gender, smoking, comorbidities, and ex-
acerbations. Only BMI loaded to other factors, particularly
in females and ex-smokers. Currently, all COPD patients
are treated similarly, despite their clinical heterogeneity.
Our study suggests that COPD can be described more
comprehensively, using simple measures available to many
healthcare professionals. Identification of COPD subtypes
may lead to the development of more specific and effec-
tive COPD management strategies.
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